Immunocore Holdings plc (IMCR)

NMS – Real Time Price. Currency in USD

30.88

+0.34 (1.11%)

At close: Jun 26, 2026, 4:00 PM EDT

31.49

+0.61 (1.98%)

After-hours: Jun 26, 2026, 6:39 PM EDT

05.06.2026

4 Biotech Stocks Investors Should Watch in 2026

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.

31.05.2026

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance Brenetafusp was generally well tolerated as monotherapy and in combination with pembrolizumab (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.

22.05.2026

Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 111.5% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

06.05.2026

Immunocore reports first quarter financial results and provides a business update

Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal melanoma Cash, cash equivalents and marketable securities of $845 million as of March 31, 2026 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.

19.04.2026

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

06.04.2026

Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference

Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.

17.03.2026

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn.

Videos

No Data

There is no data to display

Press releases

31.05.2026

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

06.05.2026

Immunocore reports first quarter financial results and provides a business update

19.04.2026

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

17.03.2026

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn.

Immunocore Holdings plc (IMCR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Immunocore Holdings plc (IMCR)

4 Biotech Stocks Investors Should Watch in 2026

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet

Immunocore reports first quarter financial results and provides a business update

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Videos

No Data

Press releases

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Immunocore reports first quarter financial results and provides a business update

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

4 Biotech Stocks Investors Should Watch in 2026

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet

Immunocore reports first quarter financial results and provides a business update

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Videos

No Data

Press releases

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Immunocore reports first quarter financial results and provides a business update

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Search stocks

Immunocore Holdings plc (IMCR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Immunocore Holdings plc (IMCR)

4 Biotech Stocks Investors Should Watch in 2026

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet

Immunocore reports first quarter financial results and provides a business update

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Videos

No Data

Press releases

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Immunocore reports first quarter financial results and provides a business update

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

4 Biotech Stocks Investors Should Watch in 2026

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet

Immunocore reports first quarter financial results and provides a business update

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Videos

No Data

Press releases

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Immunocore reports first quarter financial results and provides a business update

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting